Related by context. Frequent words. (Click for all words.) 65 Investigational Device Exemption 65 BLA submission 62 Investigational Device Exemption IDE 61 phase IIa 60 registrational 59 Pivotal Trial 58 multicenter clinical 58 Pivotal Phase III 58 phase IIb 57 glatiramer acetate 57 Marketing Authorization Application 57 Phase 2b study 57 Phase 2a trial 57 alvimopan 57 Azedra 57 Cethrin 57 Phase III 56 Phase IIa clinical trials 56 FIRAZYR 56 placebo controlled clinical 56 ATTRACT 56 investigational 56 Phase IIb 56 orphan designation 55 Biologics License Application BLA 55 randomized controlled clinical 55 Mutual Recognition Procedure 55 PA# [002] 55 Pirfenidone 55 ROTATEQ 55 methylnaltrexone 55 Neuradiab 55 PROPEL trial 55 double blinded placebo 55 Phase 2b trial 55 multicentre 55 Phase II 55 clinical trial 55 Phase III clinical 54 multicenter study 54 ZOSTAVAX 54 placebo controlled studies 54 Stedivaze 54 CORTOSS 54 TORISEL 54 Orphan Drug status 54 Phase Ib 54 Phase IIa trial 54 label multicenter 54 Amrubicin 54 prospective observational 54 INDs 54 Phase IIa 54 Alemtuzumab 54 randomized controlled clinical trials 54 confirmatory Phase III 54 NDA submission 54 silodosin 54 Phase 2b clinical 54 EORTC 54 PREOS 53 Phase 2a 53 romiplostim 53 Torisel 53 prospective randomized controlled 53 Phase III pivotal 53 Investigational 53 PFO closure 53 Phase III clinical trials 53 PROMACTA 53 HCV protease inhibitor 53 Phase 1a 53 placebo controlled randomized 53 confirmatory Phase 3 53 pharmacokinetic studies 53 Clinical Study 53 Pivotal Phase 53 Ceftobiprole 53 active comparator 53 Icatibant 53 Phase Ia 53 diabetic neuropathic pain 53 BAY #-# 53 ATryn R 53 Phase IIa clinical 53 NSABP 52 pivotal Phase III 52 Orphan Drug Status 52 Cinryze TM 52 Nimotuzumab 52 biologic therapy 52 randomized Phase III 52 Rhucin ® 52 pseudobulbar affect PBA 52 teduglutide 52 placebo controlled trials 52 multicenter randomized double 52 Complete Response 52 Genasense R oblimersen 52 Biologics License Application 52 Phase 1b